An Open-label, Pharmacokinetic, Pharmacodynamic, and Tolerability Study of AVE5026 Administered at Weight-adjusted Doses to Patients Less Than 18 Years of Age With a Central Venous Line (CVL) [Estudio abierto, de farmacocinética y farmacodinámica, y tolerabilidad de AVE5026 administrado en dosis ajustadas al peso a pacientes menores de 18 años con una vía venosa central (VVC)]

Trial Profile

An Open-label, Pharmacokinetic, Pharmacodynamic, and Tolerability Study of AVE5026 Administered at Weight-adjusted Doses to Patients Less Than 18 Years of Age With a Central Venous Line (CVL) [Estudio abierto, de farmacocinética y farmacodinámica, y tolerabilidad de AVE5026 administrado en dosis ajustadas al peso a pacientes menores de 18 años con una vía venosa central (VVC)]

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 May 2016

At a glance

  • Drugs Semuloparin (Primary)
  • Indications Thromboembolism
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Sanofi
  • Most Recent Events

    • 14 Jan 2013 Primary endpoint amended as reported by ClinicalTrials.gov.
    • 11 Jul 2012 Planned End Date changed from 1 Sep 2014 to 1 Jul 2012 as reported by ClinicalTrials.gov.
    • 11 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top